When IV is mandatory

P. Pelosi (Milano, Italy)

Source: Annual Congress 2009 - Practical Workshop - Noninvasive and invasive ventilation: looking for the right time
Session: Practical Workshop - Noninvasive and invasive ventilation: looking for the right time
Session type: Practical Workshop
Number: 4166
Disease area: Respiratory critical care

Slide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Pelosi (Milano, Italy). When IV is mandatory. Annual Congress 2009 - Practical Workshop - Noninvasive and invasive ventilation: looking for the right time

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Factors affecting smear and culture conversion durations of category I, II and IV tuberculosis patients
Source: Eur Respir J 2004; 24: Suppl. 48, 649s
Year: 2004

Collagen I, III and IV content in airways and lung parenchyma of COPD patients
Source: Annual Congress 2010 - Proteases and the matrix
Year: 2010

NSCLC stage IV
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Longitudinal bronchoscopy findings in children with mucopolysaccharidosis II (MPS II)
Source: Virtual Congress 2020 – From the bronchoscope to the clinic: paediatric bronchology at a glance
Year: 2020


Heterogeneity of stage III and its implication on treatment
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Indication and results of surgery in stage III NSCLC
Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology
Year: 2010



Prerequisites, potential and limits of thoracic surgery with curative intent for stage III NSCLC
Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Year: 2019


COPD assessment: I, II, III, IV and/or A, B, C, D
Source: Eur Respir J 2014; 43: 949-950
Year: 2014


Which definition for IIIA N2?
Source: Annual Congress 2013 –The management of N2 disease in non-small cell lung cancer
Year: 2013


Daily vs weekly administration of epoetin- beta for the control of lung cancer – related anaemia after combination chemoterapy in patients with NSCCL (stage IIIa, IIIb and IV)
Source: Eur Respir J 2006; 28: Suppl. 50, 755s
Year: 2006

Postoperative adjuvant treatment in stage III NSCLC
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007

Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Intraoperative photodinamic therapy as a part of combined radical treatment for stage III NSCLC
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011



Diagnostic work-up in stage III NSCLC including assessment of fitness for radical therapy
Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Year: 2019


A single centre review of palliative chemotherapy in newly diagnosed stage IIIb and IV lung cancer patients with good performance status
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013


Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
Source: Eur Respir Rev 2015; 24: 340-355
Year: 2015



Improved results after preoperative concurrent chemotherapy and high dose radiation therapy in selected cases with stage III N2 lung cancer?
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012